Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000902 · ClinicalTrials.gov registry record · Phase 1
A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 217
- Enrollment target
NCT00000902: Completed Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000902 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 217 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (262% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000902, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 217 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the value of changing anti-HIV medications in children with progressive HIV disease who have received previous treatment. Plasma viral load (the level of HIV in the blood) is probably most effectively reduced by giving patients anti-HIV drugs which affect the virus at various stages of development. Changing the medications may enhance the results of treatment.
Interventions
- DRUG Lamivudine
- DRUG Ritonavir
- DRUG Stavudine
- DRUG Nelfinavir mesylate
- DRUG Nevirapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Est. Completion | 2002-04 |
| Phase | Phase 1 |
What the finished NCT00000902 record still lists
NCT00000902 is an interventional study that assigns participants to a tested intervention. The registered 217 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (262% higher).
The record links to 0 conditions, and to 5 interventions - of which Lamivudine is the first listed.
NCT00000902 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000902 about?
NCT00000902 is a clinical study titled "A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment". The purpose of this study is to determine the value of changing anti-HIV medications in children with progressive HIV disease who have received previous treatment. Plasma viral load (the level of HIV in the blood) is probably most effectively reduced by giving patients anti-HIV drugs which affect t...
What is the current status of trial NCT00000902?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 217 participants. Estimated completion is 2002-04.
What interventions are being tested in trial NCT00000902?
The interventions under investigation include: Lamivudine (DRUG), Ritonavir (DRUG), Stavudine (DRUG), Nelfinavir mesylate (DRUG), Nevirapine (DRUG).
Who is sponsoring clinical trial NCT00000902?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00000902's enrollment target sits among peer trials
217 240th of 2000 higher than 1,758 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05079282 · 217 participants · Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
- NCT05470439 · 217 participants · NA
My Interprofessional Care Team for Adherence and Research Engagement Disparities
- NCT05981703 · 217 participants · Phase 1
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- NCT06342258 · 217 participants · Phase 1
COES: Curing Order Effects on Sealants